Showing results 1 to 20 of 47
next >
| Issue Date | Title | Author(s) |
| 1-Jun-2023 | ALMB-0168, a novel Cx43 hemichannel agonist monoclonal antibody, for metastatic or unresectable osteosarcoma after standard chemotherapy: A multicenter, open-label, single-arm, phase 1 study | Shen, Jingnan; Guo, Wei; Wang, Jin; Xie, Xianbiao; Xie, Lu; Xu, Jie; Jing, Chen; Lin, Jianhua; Li, Xianan; Zhou, Yong; Wang, Guowen; Zhang, Xiaojing; Yao, Weitao; Dong, Yang; Ye, Zhaoming; Wang, Li; Zeng, Yanyan; Wu, Yongyong; Yang, Xiugao; Zhang, Yanfeng |
| 2019 | Anlotinib and irinotecan for advanced Ewing sarcoma after failure of standard therapy: A multicenter, two-cohort, single-arm, open label, phase Ib/II trial (NCT03416517). | Xu, Jie; Xie, Lu; Guo, Wei; Tang, Xiaodong; Yang, Rongli; Yan, Taiqiang; Liu, Kuisheng; Gu, Jin |
| Mar-2021 | Anlotinib, Vincristine, and Irinotecan for Advanced Ewing Sarcoma After Failure of Standard Multimodal Therapy: A Two-Cohort, Phase Ib/II Trial | Xu, Jie; Xie, Lu; Sun, Xin; Liu, Kuisheng; Tang, Xiaodong; Yan, Taiqiang; Yang, Rongli; Guo, Wei; Gu, Jin |
| 2020 | Anorexia, Hypertension, Pneumothorax, and Hypothyroidism: Potential Signs of Improved Clinical Outcome Following Apatinib in Advanced Osteosarcoma | Xie, Lu; Xu, Jie; Sun, Xin; Tang, Xiaodong; Yan, Taiqiang; Yang, Rongli; Guo, Wei |
| 2017 | Anti-angiogenesis target therapy for advanced osteosarcoma | Xie, Lu; Ji, Tao; Guo, Wei |
| 1-Jun-2024 | Apatinib combined with ifosfamide and etoposide versus ifosfamide and etoposide in relapsed or refractory osteosarcoma (OAIE/PKUPH-sarcoma 11): A multicenter, randomized controlled trial | Xie, Lu; Xu, Jie; Sun, Xin; Liang, Xin; Liu, Kuisheng; Sun, Kunkun; Li, Yuan; Liu, Rong; Wang, Du; Shao, Shurong; Li, Peiyu; Pang, Zheng; Zhou, Guangxin; Wu, Sujia; Hua, Yingqi; Hu, Haiyan; Yang, Yi; Ji, Tao; Guo, Wei; Tang, Xiaodong |
| 2018 | Apatinib for advanced osteosarcoma after failure of standard multimodal therapy: An open label phase 2 clinical trial. | Xie, Lu; Xu, Jie; Sun, Xin; Tang, Xiaodong; Yan, Taiqiang; Yang, Rongli; Guo, Wei |
| 2019 | Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial | Xie, Lu; Xu, Jie; Sun, Xin; Tang, Xiaodong; Yan, Taiqiang; Yang, Rongli; Guo, Wei |
| 2018 | Apatinib for advanced sarcoma: results from multiple institutions' off-label use in China | Xie, Lu; Guo, Wei; Wang, Ye; Yan, Taiqiang; Ji, Tao; Xu, Jie |
| 2020 | Apatinib for Treatment of Inoperable Metastatic or Locally Advanced Chondrosarcoma: What We Can Learn About the Biological Behavior of Chondrosarcoma from a Two-Center Study | Xie, Lu; Xu, Jie; Sun, Xin; Liu, Kuisheng; Li, Xiaowei; He, Fangzhou; Liu, Xinyu; Gu, Jin; Lv, Zhe; Yang, Rongli; Tang, Xiaodong; Yan, Taiqiang; Li, Dasen; Yang, Yi; Dong, Sen; Sun, Kunkun; Shen, Danhua; Guo, Wei |
| 2020 | Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial | Xie, Lu; Xu, Jie; Sun, Xin; Guo, Wei; Gu, Jin; Liu, Kuisheng; Zheng, Bingxin; Ren, Tingting; Huang, Yi; Tang, Xiaodong; Yan, Taiqiang; Yang, Rongli; Sun, Kunkun; Shen, Danhua; Li, Yuan |
| 2019 | Apatinib plus camrelizumab (SHR-1210) for unresectable high-grade osteosarcoma (APFAO) progressing after chemotherapy: A prospective, open label, phase II trial. | Xie, Lu; Guo, Wei; Xu, Jie; Sun, Xin; Liu, Kuisheng; Zheng, Bingxin; Ren, Ting; Huang, Yi; Tang, Xiaodong; Yan, Taiqiang; Yang, Rongli; Sun, Kunkun; Shen, Danhua; Li, Yuan |
| 20-May-2021 | Apatinib plus ifosfamide and etoposide (IE) versus IE chemotherapy alone for relapsed or refractory osteosarcoma. | Xie, Lu; Guo, Wei; Xu, Jie; Gu, Jin; Tang, Xiaodong; Li, Yuan; Sun, Kunkun |
| Jul-2021 | Apatinib plus ifosfamide and etoposide for relapsed or refractory osteosarcoma: A retrospective study in two centres | Xie, Lu; Xu, Jie; Sun, Xin; Li, Xiaowei; Liu, Kuisheng; Liang, Xin; Zhou, Zuli; Zhuang, Hongqing; Sun, Kunkun; Wu, Yiming; Gu, Jin; Guo, Wei |
| Dec-2023 | Benefit of Using Both Ultrasound Imaging and Clinical Information for Predicting Malignant Soft Tissue Tumors | Zhang, Yusen; Zhao, Chenyang; Lv, Heng; Dong, Licong; Xie, Lu; Tian, Yun; Wu, Wangjie; Luo, Haiyu; Yang, Qi; Liu, Li; Sun, Desheng; Xie, Haiqin |
| 1-Jun-2022 | Clinical implications of next-generation sequencing on pediatric solid tumors. | Guo, Wei; Xie, Lu; Xu, Jie; Chen, Lijuan; Wang, Liwei; Wang, Aodi; Wang, Mingmin; Dong, Xiaowei; Mei, Lei; Chen, Hui; Yuan, Shaohua; Wang, Kai |
| 7-Apr-2021 | The Clinical Implications of Tumor Mutational Burden in Osteosarcoma | Xie, Lu; Yang, Yufei; Guo, Wei; Che, Dongxue; Xu, Jie; Sun, Xin; Liu, Kuisheng; Ren, Tingting; Liu, Xingyu; Yang, Yi; Ji, Tao; Tang, Xiaodong |
| 31-Mar-2021 | Complete remission of metastatic osteosarcoma using combined modality therapy: a retrospective analysis of unselected patients in China | Xie, Lu; Xu, Jie; Li, Xiaowei; Zhou, Zuli; Zhuang, Hongqing; Sun, Xin; Liu, Kuisheng; Liu, Xingyu; Sun, Kunkun; Wu, Yiming; Gu, Jin; Guo, Wei |
| 15-Jun-2022 | Distinct genetic features between osteosarcomas firstly metastasizing to bone and to lung | Xie, Lu; Cai, Zhenyu; Tang, Xiaodong; Guo, Wei; Meng, Fanfei; Zhang, Xin; Shi, Xiaoliang; Pang, Fei |
| May-2023 | Distinct genomic features between osteosarcomas firstly metastasing to bone and to lung | Xie, Lu; Cai, Zhenyu; Lu, Hezhe; Meng, Fanfei; Zhang, Xin; Luo, Kun; Su, Xiaoxing; Lei, Yan; Xu, Jiuhui; Lou, Jingbing; Wang, Han; Du, Zhiye; Wang, Yunfan; Li, Yuan; Ren, Tingting; Xu, Jie; Sun, Xin; Tang, Xiaodong; Guo, Wei |
